TOP TEN perturbations for 1553876_at (Homo sapiens)

Organism: Homo sapiens
Gene: 1553876_at
Selected probe(set): 1553876_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 1553876_at (1553876_at) across 6622 perturbations tested by GENEVESTIGATOR:

septic shock study 3 (D1; survivor) / normal blood sample

Relative Expression (log2-ratio):-3.1975946
Number of Samples:34 / 22
Experimental septic shock study 3 (D1; survivor)
Blood samples from patients (survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D3; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-3.0250778
Number of Samples:9 / 22
Experimental septic shock study 3 (D3; non-survivor)
Blood samples from patients (non-survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D2; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-2.9694967
Number of Samples:8 / 22
Experimental septic shock study 3 (D2; non-survivor)
Blood samples from patients (non-survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D1; non-survivor) / normal blood sample

Relative Expression (log2-ratio):-2.8793507
Number of Samples:17 / 22
Experimental septic shock study 3 (D1; non-survivor)
Blood samples from patients (non-survivors) collected at day 1 (D1) after the septic shock onset. According to day 28 survival status, patients were classified as non-survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D2; survivor) / normal blood sample

Relative Expression (log2-ratio):-2.8072424
Number of Samples:12 / 22
Experimental septic shock study 3 (D2; survivor)
Blood samples from patients (survivors) collected at day 2 (D2) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

septic shock study 3 (D3; survivor) / normal blood sample

Relative Expression (log2-ratio):-2.4776697
Number of Samples:22 / 22
Experimental septic shock study 3 (D3; survivor)
Blood samples from patients (survivors) collected at day 3 (D3) after the septic shock onset. According to day 28 survival status, patients were classified as survivors. Septic shock patients were identified according to the diagnostic criteria of the American College of Chest Physicians/Society of Critical Care Medicine (1992). The onset of septic shock was defined as the beginning of vasopressor therapy in combination with an identifiable site of infection, persisting hypotension - despite fluid resuscitation - and evidence of a systemic inflammatory response manifested by at least two of the following criteria: a) temperature >38ºC or <36ºC; b) heart rate >90 beats/min; c) respiratory rate >20 breaths/min; d) white blood cell count >12,000/mm3 or <4000/mm3. Excluded were subjects that were less than 18 years old and had aplasia or immunosuppressive disease (e.g. HIV infection).
Control normal blood sample
Blood samples from healthy subjects.

cutaneous T-cell lymphoma study 1 (tumor phase) / normal skin tissue

Relative Expression (log2-ratio):2.1293955
Number of Samples:4 / 8
Experimental cutaneous T-cell lymphoma study 1 (tumor phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the tumor phase (extranodal).
Control normal skin tissue
Skin biopsies from healthy individuals.

cutaneous T-cell lymphoma study 1 (plaque phase) / normal skin tissue

Relative Expression (log2-ratio):1.5636511
Number of Samples:7 / 8
Experimental cutaneous T-cell lymphoma study 1 (plaque phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the plaque phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

cutaneous T-cell lymphoma study 1 (patch phase) / normal skin tissue

Relative Expression (log2-ratio):1.3677778
Number of Samples:2 / 8
Experimental cutaneous T-cell lymphoma study 1 (patch phase)
Lesional skin biopsies from patients with cutaneous T-cell lymphoma in the patch phase.
Control normal skin tissue
Skin biopsies from healthy individuals.

dendritic cell study 6 (gardiquimod; RN486) / dendritic cell study 6 (gardiquimod)

Relative Expression (log2-ratio):1.2332611
Number of Samples:4 / 7
Experimental dendritic cell study 6 (gardiquimod; RN486)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) and RN486 (Bruton’s tyrosine kinase; BTK inhibitor) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.
Control dendritic cell study 6 (gardiquimod)
Plasmacytoid dendritic cells (pDCs) collected from blood of healthy donors and treated with gardiquimod (TLR7 agonist) for 3 hours. pDCs were sorted as CD303+, CD123+, CD45+, CD69+, CD40+, CD86+.